Biotie Therapies
As of the edition of 20 October 2026, Biotie Therapies runs 5 drugs; it is on route A at 3 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Biotie Therapies was acquired in 2016; successor Acorda Therapeutics.
- Biotie Therapies Inc.: acquired in 2016; successor Acorda Therapeutics
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 3 |
| Stopped | 2 |
| Total | 5 |
Where it needs a new molecule
Route A at 3 targets, route B at 0 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Biotie Therapies needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 4 trials led
- Bones, joints and muscles: 1 trials led
- Chemically induced: 1 trials led